BNTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

BioNTech SE

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 10, 2026

$89.21+1.50 (+1.71%)

Close on Oct 19, 2026

Earnings

Quarterly results announced on Form 8-K, Item 2.02

Quarter	Reported	Time	Revenue	EPS (GAAP)	EPS (adjusted)
Q4 FY2025 Ended Dec 31, 2025	Mar 10, 2026	Before market open	$907.40M	$-1.25	$-0.33
Q4 FY2024 Ended Dec 31, 2024	Mar 10, 2025	Before market open	$1.19B	$1.08	–
Q4 FY2023 Ended Dec 31, 2023	Mar 20, 2024	Before market open	$1.48B	$1.90	–

Company guidance

Outlook given with results on Mar 10, 2026, compared with the previous outlook

Measure	Period	Guidance	vs. prior
adjusted SG&A expensesnon-GAAP	2026	700 to 800	Raised
adjusted R&D expensesnon-GAAP	2026	2.2 to 2.5	New
total revenues	2026	2 to 2.3	New

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements BioNTech filed with the SEC

Oct 19, 2026, 7:26 AM ET
BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026
EX-99.1 to Form 6-K
Oct 13, 2026, 4:08 PM ET
BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer
EX-99.1 to Form 6-K
Sep 14, 2026, 8:28 AM ET
BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients
EX-99.1 to Form 6-K
Aug 28, 2026, 9:06 AM ET
BioNTech Provides Update on Phase 2 Clinical Trial of Autogene Cevumeran in Resected Colorectal Cancer
EX-99.1 to Form 6-K
Aug 27, 2026, 4:54 PM ET
Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
EX-99.1 to Form 6-K
Aug 20, 2026, 7:36 AM ET
BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum
EX-99.1 to Form 6-K
Aug 4, 2026, 7:01 AM ET
UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
EX-99.1 to Form 6-K
Aug 4, 2026, 7:00 AM ET
BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update
EX-99.1 to Form 6-K
Aug 4, 2026, 7:00 AM ET
Second Quarter 2026 Financial Results & Corporate Update August 4, 2026 Exhibit 99.1
EX-99.2 to Form 6-K
Aug 3, 2026, 6:54 AM ET
BioNTech Announces Appointment of Guido Oelkers to
EX-99.1 to Form 6-K
Jul 29, 2026, 5:08 PM ET
European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
EX-99.1 to Form 6-K
Jun 8, 2026, 8:01 AM ET
Disclosure of share buyback program pursuant to Art. 5(1) lit. a) of the Regulation (EU) No. 596/2014 and Art. 2(1) of the Delegated Regulation (EU) 2016/1052
EX-99.1 to Form 6-K
Jun 1, 2026, 7:59 AM ET
Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
EX-99.1 to Form 6-K
May 22, 2026, 8:03 AM ET
BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
EX-99.1 to Form 6-K
May 15, 2026, 4:18 PM ET
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026
EX-99.1 to Form 6-K
May 15, 2026, 4:18 PM ET
Annual General Meeting 15 May 2026, 14:00 CEST Exhibit 99.2
EX-99.2 to Form 6-K
May 15, 2026, 4:18 PM ET
EX-99.3 to Form 6-K
EX-99.3 to Form 6-K
May 7, 2026, 8:20 AM ET
BioNTech Announces New ADS Repurchase Program
EX-99.1 to Form 6-K
May 5, 2026, 6:49 AM ET
UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
EX-99.1 to Form 6-K
May 5, 2026, 6:47 AM ET
BioNTech Announces First Quarter 2026 Financ ial Results and Corporate Update
EX-99.1 to Form 6-K
May 5, 2026, 6:47 AM ET
First Quarter 2026 Financial Results & Corporate Update May 5, 2026 Exhibit 99.2
EX-99.2 to Form 6-K
Apr 13, 2026, 7:55 AM ET
BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer
EX-99 to Form 6-K
Apr 2, 2026, 4:15 PM ET
the German language version is decisive
EX-99.1 to Form 6-K
Mar 24, 2026, 5:09 PM ET
BioNTech Clinical Data at ELCC 2026 Highlight Potential of
EX-99.1 to Form 6-K
Mar 10, 2026, 6:53 AM ET
BioNTech Announces Fourth Quarter and Full Year 2025 Financ ial Results and Corporate Update
EX-99.1 to Form 6-K
Mar 10, 2026, 6:53 AM ET
4th Quarter & Full Year 2025 Financial Results & Corporate Update March 10th, 2026 Exhibit 99.2
EX-99.2 to Form 6-K
Mar 10, 2026, 6:34 AM ET
BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030
EX-99.1 to Form 6-K
Jan 28, 2026, 8:10 AM ET
BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer
EX-99.1 to Form 6-K
Jan 13, 2026, 6:18 PM ET
Translating Science into Survival Prof. Dr. Ugur Sahin, M.D., CEO & Co-founder, BioNTech 44th J.P. Morgan Healthcare Conference January 13, 2026 Exhibit 99.1
EX-99.1 to Form 6-K
Jan 12, 2026, 6:57 AM ET
BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44 th Annual J.P. Morgan Healthcare Conference
EX-99.1 to Form 6-K
Jan 6, 2026, 6:02 AM ET
Convenience Translation. The German version is authoritative
EX-99.1 to Form 6-K
Dec 18, 2025, 4:15 PM ET
CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field
EX-99.1 to Form 6-K
Dec 9, 2025, 7:25 AM ET
BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer
EX-99.1 to Form 6-K
Dec 8, 2025, 6:37 AM ET
BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
EX-99.1 to Form 6-K
Dec 3, 2025, 4:30 PM ET
BioNTech Achieves Minimum Condition in CureVac Exchange Offer
EX-99.1 to Form 6-K
Nov 26, 2025, 4:33 PM ET
BioNTech Shares Progress on Exchange Offer for CureVac Shares
EX-99.1 to Form 6-K
Nov 12, 2025, 7:45 AM ET
Innovation Series: R&D Day 2025 November 11th, 2025 Exhibit 99.1
EX-99.1 to Form 6-K
Nov 3, 2025, 6:50 AM ET
UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
EX-99.1 to Form 6-K
Nov 3, 2025, 6:49 AM ET
BioNTech Announces Third Quarter 2025 Financ ial Results and Corporate Update
EX-99.1 to Form 6-K
Nov 3, 2025, 6:49 AM ET
3rd Quarter 2025 Financial Results & Corporate Update November 3rd, 2025 Exhibit 99.2
EX-99.2 to Form 6-K

Where these numbers come from

Parsed from the XBRL in BioNTech's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BNTX.

Revenue growth4.3% · median -9.2%

Gross margin77.6% · median 59.9%

Operating margin-49.0% · median -54.6%

Net margin-39.6% · median -53.0%

Company	Revenue	Growth
BNTX	€2.87B	+4.3%
EXEL	$2.44B	+9.2%
MRNA	$2.23B	-27.6%
QGEN	–	–
ALVO	–	–
IMTX	–	–

Company

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 500
Held by institutions: 18.9%
Auditor: EY GmbH & Co. KG Wirtschaftsprufungsgesellschaft
SEC CIK: 1776985

Advertisement
300 × 250